Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site

Journal of Clinical Oncology

Volumn 20, Issue 24, 2002, Pages 4679-4683

  Culine, Stéphane ^a   Kramar, Andrew ^a   Saghatchian, Mahasti ^a   Bugat, Roland ^a   Lesimple, Thierry ^a   Lortholary, Alain ^a   Merrouche, Yacine ^a   Laplanche, Aqnès ^a   Fizazi, Karim ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; VALIDATION PROCESS;

ANALYSIS OF VARIANCE; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; SURVIVAL RATE;

EID: 0037115537     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.04.019     Document Type: Article

References (18)

1. Hainsworth JD, Greco FA: Treatment of patients with cancer of an unknown primary site. N Engl J Med 329:257-263, 1993
2. Sporn JR, Greenberg BR: Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. Semin Oncol 20:261-267, 1993
3. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
4. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-167, 1966
5. Saghatchian M, Fizazi K, Borel C, et al: Carcinoma of unknown primary site: A chemotherapy strategy based on histological differentiation - Results of a prospective study. Ann Oncol 12:535-540, 2001
6. Lortholary A, Culine S, Bouzy J, et al: Cisplatin in combination with either gemcitabine (GC) or irinotecan (IC) in carcinomas of unknown primary (CUP): Results of a randomized phase II study. Proc Am Soc Clin Oncol 21:153a, 2002 (abstr 609)
7. Daugaard G: Unknown primary tumours. Cancer Treat Rev 20:119-147, 1994
8. Rigg A, Cunningham D, Gore M, et al: A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic carcinoma. Br J Cancer 75:101-105, 1997
9. Greco FA, Gray J, Burris HA, et al: Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 7:203-212, 2001
10. Hainsworth JD, Erland JB, Kalman LA, et al: Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15:1651-1656, 1997
11. Greco FA, Burris HA, Litchy S, et al: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol 20:1651-1656, 2002
12. Kambhu SA, Kelsen DP, Fiore J, et al: Metastatic adenocarcinomas of unknown primary site: Prognostic variables and treatment results. Am J Clin Oncol 13:55-60, 1990
13. Hainsworth JD, Johnson DH, Greco FA: Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience. J Clin Oncol 10:912-922, 1992
14. Abbruzzese JL, Abbruzzese MC, Hess KR, et al: Unknown primary carcinoma: Natural history and prognostic factors in 657 patients. J Clin Oncol 12:1272-1280, 1994
15. Van der Gaast A, Verweij J, Planting AST, et al: Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 13:1720-1725, 1995
16. Hess KR, Abbruzzese MC, Lenzi R, et al: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403-3410, 1999
17. Culine S, Fabbro M, Ychou Y, et al: Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy. Ann Oncol 10:569-575, 1999
18. Culine S, Fabbro M, Ychou Y, et al: Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 94:840-846, 2002